Short- and long-term management of heartburn and other acid-related disorders: Development of an algorithm for primary care providers

Journal of Family Practice

Volumn 58, Issue 7, 2009, Pages

  Fennerty, M Brian ^a   Finke, Karen B ^b   Kushner, Pamela R ^c   Peura, David A ^b   Record, Laura ^d   Riley, Laryl ^e   Ruoff, Gary E ^f   Simonson, William ^g   Wright, Wendy L ^h  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d First Choice Medical Associates   (United States)

^e Gastroenterology Specialists Inc   (United States)

^f MICHIGAN STATE UNIVERSITY   (United States)

^g School of Medicine ^*

^h USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; ATTAPULGITE; BICARBONATE; BISMUTH SALICYLATE; BISPHOSPHONIC ACID DERIVATIVE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CIPROFLOXACIN; CYCLOSPORIN; CYCLOSPORIN A; DEXLANSOPRAZOLE; DIHYDROXYALUMINUM SODIUM CARBONATE; ESOMEPRAZOLE; FAMOTIDINE; FLUOXETINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IRON; ISONIAZID; KAPIDEX; KETOCONAZOLE; LANSOPRAZOLE; MIDAZOLAM; NIFEDIPINE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OMEPRAZOLE DERIVATIVE; PANTOPRAZOLE; PHENYTOIN; POTASSIUM CHLORIDE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SILDENAFIL; SIO PHYLLIN; TETRACYCLINE; THEOPHYLLINE; TUMS; UNCLASSIFIED DRUG; UNINDEXED DRUG; XOLEGEL;

ABDOMINAL PAIN; ALGORITHM; CONFUSION; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DUODENUM ULCER; DYSPEPSIA; EROSIVE GASTRITIS; ESOPHAGITIS; FATIGUE; FLATULENCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEALTH CARE PERSONNEL; HEARTBURN; HIP FRACTURE; HUMAN; LONG TERM CARE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; REFLUX ESOPHAGITIS; REVIEW; SHORT COURSE THERAPY; STOMACH ULCER; TREATMENT DURATION; ZOLLINGER ELLISON SYNDROME;

ACUTE DISEASE; ALGORITHMS; ANTACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; DYSPEPSIA; ESOPHAGITIS; HEARTBURN; HISTAMINE H2 ANTAGONISTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 67650505527     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Richter JE. The many manifestations of gastroesophageal reflux disease: presentation, evaluation, and treatment. Gastroenterol Clin North Am. 2007;36:577-599. (Pubitemid 47577500)
2. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900-1920. (Pubitemid 44166604)
3. Locke GR III, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448-1456.
4. Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol. 2005;3:543-552. (Pubitemid 40824747)
5. Salyers WJ Jr, Mansour A, El-Haddad B, et al. Lifestyle modification counseling in patients with gastroesophageal reflux disease. Gastroenterol Nurs. 2007;30:302-304.
6. Shaker R, Castell DO, Schoenfeld PS, et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003;98:1487-1493. (Pubitemid 36875337)
7. Zweber A, Berardi RR. Selected antacid and bismuth products. In: Zweber A, Berardi RR, Ferreri SP, et al, eds. The Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care. 16th ed. Washington, DC: American Pharmacists Association; 2009:231-246.
8. McCarthy D. Living with chronic heartburn: insights into its debilitating effects. Gastroenterol Clin North Am. 2003;32(3 suppl):S1-S9. (Pubitemid 37205752)
9. Bolin TD, Korman MG, Hansky J, et al. Heartburn: community perceptions. J Gastroenterol Hepatol. 2000;15:35-39.
10. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009;104(2 suppl):S27-S32.
11. Flook N, Jones R, Vakil N. Approach to gastroesophageal reflux disease in primary care: putting the Montreal definition into practice. Can Fam Physician. 2008;54:701-705. (Pubitemid 351838492)
12. Richter JE. Chest pain and gastroesophageal reflux disease. J Clin Gastroenterol. 2000;30(3 suppl):S39-S41. (Pubitemid 30192060)
13. Roberts R, Henderson RD, Wigle ED. Esophageal disease as a cause of severe retrosternal chest pain. Chest. 1975;67:523-526.
14. Heidelbaugh JJ, Gill AS, Van Harrison R, et al. Atypical presentations of gastroesophageal reflux disease. Am Fam Physician. 2008;78:483-488.
15. Kahrilas PJ, Shaheen NJ, Vaezi MF; American Gastroenterological Association Institute; Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease, Gastroenterology. 2008;135:1392-1413.
16. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al, for the American Gastroenterological Association. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1383-1391.
17. Leong RW, Chan FK. Drug-induced side effects affecting the gastrointestinal tract. Expert Opin Drug Saf. 2006;5:585-592. (Pubitemid 44468454)
18. Geagea A, Cellier C. Scope of drug-induced, infectious and allergic esophageal injury. Curr Opin Gastroenterol 2008;24:496-501.
19. Body JJ. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol. 2001;28(4 suppl 11):49-53. (Pubitemid 32844929)
20. Prevacid®24HR [package insert]. Deerfield, IL: Takeda Pharmaceuticals North America: 2008.
21. Prilosec [package insert]. Wilmington, DE: AstraZeneca: 2008.
22. Protonix [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; 2008.
23. Nexium [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2008.
24. Aciphex [package insert]. Woodcliff Lake, NJ; Eisai Inc.; 2009.
25. Kapidex [package insert]. Deerfield, IL: Takeda Pharmaceuticals North America, Inc.; 2009.
26. Zegerid [package insert]. San Diego, CA: Norwich Pharmaceuticals, Inc.; 2008.
27. Talley NJ, Vakil N; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol. 2005;100:2324-2337.
28. Peura DA, Gudmundson J, Siepman N, et al. Proton pump inhibitors: effective first-line treatment for management of dyspepsia. Dig Dis Sci. 2007;52:983-987. (Pubitemid 46481236)
29. Pace F, Tonini M, Pallotta S, et al. Systematic review: maintenance treatment of gastrooesophageal reflux disease with proton pump inhibitors taken 'on-demand'. Aliment Pharmacol Ther. 2007;26:195-204.
30. Inadomi JM, Fendrick AM. PPI use in the OTC era: who to treat, with what, and for how long? Clin Gastroenterol Hepatol. 2005;3:208-215.
31. Tutuian R, Castell DO. Gastroesophageal reflux disease: natural history and long-term medical and surgical outcomes. Clin Cornerstone. 2003;5:51-57. (Pubitemid 38488891)
32. Robinson M, Rodriguez-Stanley S, Miner PB, et al. Effects of antacid formulation on postprandial oesophageal acidity in patients with a history of episodic heartburn. Aliment Pharmacol Ther. 2002;16:435-443. (Pubitemid 34214522)
33. Flockhart DA, Desta Z, Mahal SK. Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions. Clin Pharmacokinet. 2000;39:295-309. (Pubitemid 30815029)
34. Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med. 2008;359:1700-1707.
35. Tagamet [package insert]. Boronia Victoria: GlaxoSmithKline Australia Pty Ltd; 2008.
36. Pepcid [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2007.
37. Axid [package insert]. Braintree, MA: Braintree Laboratories, Inc.; 2005.
38. Zantac [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009.
39. Khoury RM, Katz PO, Castell DO. Post-prandial ranitidine is superior to post-prandial omeprazole in control of gastric acidity in healthy volunteers. Aliment Pharmacol Ther. 1999;13:1211-1214. (Pubitemid 29445900)
40. Richter JE, Campbell DR, Kahrilas PJ, et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med. 2000;160:1803-1809. (Pubitemid 30418818)
41. 2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1995;9(9 suppl 1):9-14.
42. Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion - tolerance and rebound. Aliment Pharmacol Ther. 1997;11:1013-1018. (Pubitemid 27525091)
43. Rackoff A, Agrawal A, Hila A, et al. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus. 2005;18:370-373. (Pubitemid 43904763)
44. 2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002;122:625-632. (Pubitemid 34173813)
45. Rolita L, Freedman M. Over-the-counter medication use in older adults. J Gerontol Nurs. 2008;34:8-17.
46. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63:2739-2754. (Pubitemid 38049991)
47. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935-951.
48. Matheson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs. 2001;61:1801-1833. (Pubitemid 32982160)
49. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther. 2000;14:963-978.
50. Fock KM, Ang TL, Bee LC, et al. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet. 2008;47:1-6.
51. Thjodleifsson B. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors. Drugs Aging. 2002;19:911-927. (Pubitemid 36092253)
52. Vakily M, Lee RD, Wu J, et al. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Invest. 2009;29:35-50.
53. Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet. 2008;47:75-89.
54. Hatlebakk JG, Katz PO, Camacho-Lobato L, et al. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14:1267-1272. (Pubitemid 30802377)
55. 2-receptor antagonists do not compromise intragastric pH control with proton pump inhibitors. Aliment Pharmacol Ther. 2002;16:473-477. (Pubitemid 34214526)
56. Gilard M, Arnaud B, Le Gal G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006;4:2508-2509. (Pubitemid 44575451)
57. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256-260.
58. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944.
59. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA. 2008;299:532-539. (Pubitemid 351222546)
60. Coté GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:208-214.
61. Sarkar M, Hennessy S, Yang Y-X. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149:391-398.
62. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2008;27:1110-1121. (Pubitemid 351614880)
63. McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol. 2009;104(2 suppl):S5-S9.
64. Vakil N. Acid inhibition and infections outside the gastrointestinal tract. Am J Gastroenterol 2009;104(2 suppl):S17-S20.
65. Dial MS. Proton pump inhibitor use and enteric infections. Am J Gastroenterol. 2009;104(2 suppl):S10-S16.
66. Richards JB, Goltzman D. Proton pump inhibitors: balancing the benefits and potential fracture risks. CMAJ. 2008;179:306-307.
67. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179:319-326.
68. Moayyedi P, Cranney A. Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm. Am J Gastroenterol. 2008;103:2428-2431.
69. Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol. 2009;104(2 suppl):S2-S4.
70. Metz DC. Clostridium difficile colitis: wash your hands before stopping the proton pump inhibitor. Am J Gastroenterol. 2008;103:2314-2316.
71. Armstrong D, Marshall JK, Chiba N, et al, for the Canadian Association of Gastroenterology GERD Consensus Group. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol. 2005;19:15-35.
72. Richter JE, Kovacs TOG, Greski-Rose PA, et al. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther. 1999;13:795-804. (Pubitemid 29276850)
73. Pettit M. Treatment of gastroesophageal reflux disease. Pharm World Sci. 2005;27:432-435.
74. Mine S, Iida T, Tabata T, et al. Management of symptoms in step-down therapy of gastroesophageal reflux disease. J Gastroenterol Hepatol. 2005;20:1365-1370. (Pubitemid 43960833)
75. Miyamoto M, Haruma K, Kuwabara M, et al. Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine. J Gastroenterol Hepatol. 2007;22:639-644. (Pubitemid 46608387)